Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

Revicki, Dennis A.; Menter, Alan; Feldman, Steven R.; Kimel, Miriam; Harnam, Neesha; Willian, Mary Kaye

doi:10.1186/1477-7525-6-75

Cited by 42 publications

(32 citation statements)

References 27 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are consistent with the empirical findings in the adult literature, in which adult patients with plaque psoriasis report significantly impaired HRQOL relative to healthy adult populations [10,11,13,21,22], clinical levels of depression [12,20], and impaired levels of HRQOL similar to adult patients with serious chronic diseases [18]. Similar to the empirical HRQOL literature in adult patients with psoriasis [11,19,21], pediatric patients with moderate-to-severe plaque psoriasis demonstrated particularly impaired emotional functioning not only in comparison to healthy children but also in comparison to pediatric patients with arthritis, asthma, and diabetes.…”

Section: Discussionsupporting

confidence: 92%

“…Based on the empirical HRQOL literature in adult patients with psoriasis, it was hypothesized that pediatric patients with moderate-to-severe plaque psoriasis would demonstrate significantly impaired overall generic HRQOL scores in comparison to healthy children, particularly in emotional functioning [11,19,21], and would demonstrate impaired generic HRQOL comparable to other major pediatric chronic diseases [18]. In order to determine the magnitude of the differences between pediatric patients with plaque psoriasis and healthy children and pediatric patients with other chronic diseases, effect sizes were calculated [5].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases

et al. 2011

View full text Add to dashboard Cite

Health-related quality of life (HRQOL) is an important indicator of the burden of illness in moderate-to-severe plaque psoriasis. This study evaluated self-reported generic HRQOL among pediatric patients with moderate-to-severe plaque psoriasis based on pooled baseline clinical trial data and compared them to four common chronic diseases and to a healthy sample. The Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0) Generic Core Scales was administered to 208 patients ages 4 to 17 years with stable, moderate-to-severe plaque psoriasis. Patients with moderate-to-severe plaque psoriasis were compared using one-sample t-tests to published PedsQL™ ( http://www.pedsql.org ) data on healthy children and pediatric patients with arthritis, psychiatric disorders, asthma, and diabetes. Pediatric patients with moderate-to-severe plaque psoriasis demonstrated significantly impaired physical, emotional, social, and school functioning in comparison to healthy children. The PedsQL™ Emotional and School Functioning Scales demonstrated the largest mean difference between the two groups (12.1, 11.1 points, respectively). In general, patients with plaque psoriasis demonstrated significantly more impaired generic HRQOL compared to patients with diabetes, comparable HRQOL to arthritis and asthma, and better HRQOL than psychiatric patients. In conclusion, the findings indicate that pediatric patients with moderate-to-severe plaque psoriasis have significantly impaired generic HRQOL in comparison to healthy children, and HRQOL generally comparable to other serious chronic diseases. These results demonstrate the significant negative impact of plaque psoriasis on the daily lives of these children from the patients' perspective.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases

et al. 2011

View full text Add to dashboard Cite

show abstract

“…64 Other studies have reported similar functional and emotional improvements in patients with psoriasis treated with adalimumab. 64,66,68 T-cell inhibitors have also been shown to improve HRQOL scores. Alefacept signifi cantly improved diseasespecifi c quality-of-life scores in clinical trials.…”

Section: Depression and Psoriasismentioning

confidence: 97%

Depression and Quality of Life in Psoriasis

Voorhees

Fried

2009

Postgraduate Medicine

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory hyperproliferative disease of the skin, scalp, nails, and joints. The physical symptoms of psoriasis include itching, irritation, burning/stinging, sensitivity, and pain. Patients also suffer psychological distress, especially as a result of stigmatization, self-consciousness, and embarrassment, which can in turn affect employment and social activities. Relatively high rates of depression are reported in patients with psoriasis. Inflammatory cytokines such as tumor necrosis factor alpha, interferon gamma, and other type 1 cytokines play an important role in the pathogenesis and comorbidities of psoriasis. Data from both animal and human studies suggest that these cytokines are linked to depression. Some psoriasis treatments have demonstrated improvements in symptoms of psoriasis as well as in measures of depression and health-related quality of life. Physicians managing patients with psoriasis must be aware of the psychological effects of psoriasis and need to use a multifaceted approach to managing this disease, focusing on both the physical and psychological aspects.

show abstract

“…19,20 In addition to reducing the physical symptoms of psoriasis, adalimumab has been shown to improve dermatology-specific and general mental and physical HRQOL to levels comparable with that of the general population. 21 Another anti-TNF fusion protein, etanercept, has been shown to reduce fatigue and depression symptoms in patients with moderate to severe psoriasis in addition to improving psoriasis symptoms and HRQOL. 22 It is reasonable to hypothesize that adalimumab also reduces depression symptoms in patients with psoriasis.…”

mentioning

confidence: 99%

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial

Menter¹,

Augustin²,

Signorovitch

et al. 2010

Journal of the American Academy of Dermatology

Self Cite

162

160

View full text Add to dashboard Cite

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

Cited by 42 publications

References 27 publications

Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases

Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases

Depression and Quality of Life in Psoriasis

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial

Contact Info

Product

Resources

About